The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage



Status:Completed
Conditions:Atrial Fibrillation
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:January 2014
End Date:May 2014

Use our guide to learn which trials are right for you!

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis

The objective is to assess the safety and effectiveness of new dabigatran and warfarin
patients diagnosed with NVAF in the US DoD population.

Study Design:

Retrospective

Inclusion criteria:

- Patients must be continuously enrolled in a health plan during the pre-index period;

- Patients must have at least one inpatient, or one physician office visit, emergency
room visit with a diagnosis of AF (ICD-9-CM diagnosis code: 427.31in any position) on
the index date or during the pre-index period;

- Patients must have a prescription for dabigatran or warfarin (this first prescription
will be the index date);

- Patients must be treatment naive from all OAC use prior to first dabigatran or
warfarin prescription;

- Aged 18-89 on the index date;

Exclusion criteria:

- Patients with valvular procedures related to the baseline AF diagnosis will be
excluded;

- Patients with transient causes of AF such as hyperthyroidism, any cardiac surgery,
pericarditis, mycoarditis, pulmonary embolism within 3 months prior to their first
diagnosis of AF;
We found this trial at
1
site
?
mi
from
Lexington, MA
Click here to add this to my saved trials